Moderna is a company.
Moderna has raised $600.0M across 3 funding rounds.
Key people at Moderna.
Moderna has raised $600.0M in total across 3 funding rounds.
Key people at Moderna.
Moderna is a biotechnology company pioneering messenger RNA (mRNA) medicines, most notably its Spikevax COVID-19 vaccine that propelled it to prominence during the pandemic.[1][2] It serves global populations by developing vaccines and therapies for infectious diseases and cancer, addressing unmet needs in rapid-response immunization and personalized treatments amid declining post-pandemic vaccine demand.[1][2] Growth has slowed with Q3 2025 revenue at $1 billion (down 45% year-over-year) and a revised 2025 forecast of $1.6–$2 billion, but the company targets cash breakeven by 2028 through cost cuts exceeding $1 billion annually and pipeline advancements like cancer vaccines.[1][3]
Founded in 2010, Moderna emerged from mRNA technology research initially backed by DARPA and Flagship Pioneering, focusing on using synthetic mRNA to instruct cells to produce proteins for therapeutic effect.[2] CEO Stéphane Bancel, with a background in pharma operations at Eli Lilly and bioMérieux, joined early and championed the platform's potential beyond traditional vaccines.[2] The pivotal moment came during the COVID-19 pandemic when Moderna, partnering with the NIH, rapidly developed and deployed its 95% effective vaccine, generating billions in sales and validating mRNA at scale—before sales slumped post-2023, triggering restructurings.[1][2]
Moderna rides the mRNA revolution trend, shifting biotech from protein-based drugs to programmable genetic instructions, accelerated by pandemic urgency but now challenged by market saturation and policy shifts.[1][2] Timing mattered as government funding midwifed its rise, yet 2025 headwinds like HHS cuts under RFK Jr. (e.g., $766M bird flu contracts canceled) and stricter FDA approvals pressure uptake.[1][2] Favorable forces include international demand and oncology potential, where mRNA could revive stagnant cancer vaccine fields; Moderna influences the ecosystem by proving mRNA viability, spurring competitors and $6B cash reserves for sustained R&D.[2][3]
Moderna's path forward hinges on pipeline catalysts like flu/COVID combo approvals (under EU review, U.S. resubmission pending) and melanoma vaccine data, alongside deeper cost cuts and geographic expansions to offset COVID sales dips.[1][3] Trends like anti-mRNA policy risks and bird flu threats could reshape hurdles, but oncology breakthroughs may restore growth if they deliver on tantalizing early promise.[2] Its influence could evolve from pandemic hero to mRNA oncology leader—or shrink if no blockbusters emerge—tying back to its core bet: mRNA as medicine's future, now tested in a post-boom reality.[1][2][6]
Moderna has raised $600.0M in total across 3 funding rounds.
Moderna's investors include RA Capital, Acorn Bioventures, Flagship Ventures, Polaris Partners.
Moderna has raised $600.0M across 3 funding rounds. Most recently, it raised $450.0M Series E in January 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2015 | $450.0M Series E | RA Capital | |
| Nov 1, 2013 | $110.0M Venture Round | Acorn Bioventures, Flagship Ventures, Polaris Partners | |
| Dec 1, 2012 | $40.0M Venture Round | Acorn Bioventures, Flagship Ventures, Polaris Partners |
